Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5A0E

Crystal structure of cyclophilin D in complex with CsA analogue, JW47.

5A0E の概要
エントリーDOI10.2210/pdb5a0e/pdb
分子名称PEPTIDYL-PROLYL CIS-TRANS ISOMERASE F, MITOCHONDRIAL, JW47 (3 entities in total)
機能のキーワードisomerase, cyclophilin d, cyp d, ppif, cyclosporin a, csa, jw47, mitochondrial permeability transition pore, ptp, peptidylprolyl cis-trans isomerase, cyclophilin
由来する生物種HOMO SAPIENS (HUMAN)
詳細
タンパク質・核酸の鎖数4
化学式量合計38232.07
構造登録者
主引用文献Warne, J.,Pryce, G.,Hill, J.,Shi, X.,Lenneras, F.,Puentes, F.,Kip, M.,Hilditch, L.,Walker, P.,Simone, M.I.,Chan, A.W.E.,Towers, G.J.,Coker, A.R.,Duchen, M.R.,Szabadkai, G.,Baker, D.,Selwood, D.L.
Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects Against Neuro-Degeneration in Experimental Multiple Sclerosis.
J.Biol.Chem., 291:4356-, 2016
Cited by
PubMed Abstract: The mitochondrial permeability transition pore is a recognized drug target for neurodegenerative conditions such as multiple sclerosis and for ischemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, PPIF), is a positive regulator of the pore, and genetic down-regulation or knock-out improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off-target effects, immunosuppression, and toxicity. We therefore designed and synthesized a new mitochondrially targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine. X-ray analysis was used to validate the design concept, and biological evaluation revealed selective cellular inhibition of CypD and the permeability transition pore with reduced cellular toxicity compared with cyclosporine. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis, JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use.
PubMed: 26679998
DOI: 10.1074/JBC.M115.700385
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.25 Å)
構造検証レポート
Validation report summary of 5a0e
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon